Is PSE&TOSP a bad deal for Medicare?

By Ryan Foy | 02/08/17 12:06:03As a new batch of pharmaceutical drugs from major drugmakers get ready to hit the market, many Medicare patients will soon see the expiration of their coverage, if not their lives.

Medicare has made no secret about the fact that they have been reluctant to change the law that has guaranteed the elderly with medical conditions the right to obtain prescription medications, especially in times of rising costs and shortages.

But with the release of the latest batch of PSE-based medicines, Medicare has changed its tune.

According to a report published by the nonprofit Center for Medicare and Medicaid Services (CMS), which is coordinating the rollout, the PSE medicines are supposed to be a “safer” alternative to traditional Medicare drugs that the drugmakers can use to treat chronic conditions.

While the report was issued as the deadline to sign up for the next round of Pse&amp.TOSPs approached, the CMS released an update that says that the Pse medicines are “more effective” and “lower costs than existing prescription drugs.”

Pse>TosPs are supposed be “less expensive” and are “less effective”than traditional medications, the agency said in the update. 

The update also says that “Medicare is working with PSE to make sure that all seniors have access to the drugs.”

What the drug companies are trying to do with Pse medications is “not just reduce the costs of these drugs but also increase the value of these medications,” the report says.

“Medicare should not allow Medicare to be used as a backdoor to buy these drugs, and Medicare should not be incentivized to provide Pse products to seniors,” Dr. David Katz, an assistant professor at the University of Michigan School of Public Health and Health Services, told Engadge.

“Instead of Medicare buying Pse, it should be giving seniors access to these drugs.”

Katz told Engaad that while PSEs are not cheap, they’re not a waste of money, especially when they’re offered to Medicare beneficiaries.

“They’re very cost-effective and the drugmaker can make them cheaper by reducing the cost of the drugs to Medicare,” Katz said. 

“I think it’s a very sensible policy to encourage seniors to take these drugs because it saves Medicare money, and it saves lives.”

Medicare currently reimburses about half of the costs for the Psi&amp, T-PosP and other medicines that the companies are marketing to seniors.

The update said that “the PSE medications are being made available through an online portal and that these drugs will be reimbursed by Medicare over the next three years.”

The PSE drugs are being offered through a portal that includes the Ptsh&amp ;D&amp%;Med-Ptsh;D website.

The Ptsch&amp.;D website is a drug development and research center run by pharmaceutical giant Pfizer.

The website offers a selection of drug development, clinical trials and drug approval documents.

The Drug and Device Administration, the federal agency that regulates pharmaceuticals, also approved Pts&”D’s drug to treat psoriasis, the report states.

The drugs that are being tested in the portal are not approved by the FDA.

However, the Drug and Tmsource is still reviewing the Ps&amp&;Ps drug that Pfizer is testing, the update says.

If Pfizer’s drug does not make it to market, the company could be on the hook for a $1.9 billion fine. 

Pfizer did not immediately respond to a request for comment from Engadgy.

Pts&gt.;D is being developed by Pfizer and the University at Buffalo in partnership with the University Hospitals of Buffalo, New York and the National Institutes of Health.